| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Kestra Medical Technologies, Ltd.$21.73
+0.79 (+3.82%)
F 13Pipeline Score MedTech · Commercial
Market Cap
1.26 B
EPS
-2.81
P/E Ratio
-
Value Trade
9.02 M
SEC Financials
Q1 2026Dilution Risk
Revenue
24.55 M
R&D Expenses
4.97 M
Total Assets
379.34 M
Total Liabilities
91.35 M
Equity
287.99 M
D/E Ratio
12,345
0.56 %
Week
-8.31 %
1 Month
-17.4 %
3 Month
-12.71 %
6 Month
-5.71 %
5 Year
-5.71 %
All Time
Cash Data
Cash Position
291.32 M
Monthly Burn
11.59 M
Runway
22 mo
Burn Trend
StableSEC Filing
Mar 17, 2026
Overview
Volume
30.56 K
52 Week Range
13.25 - 30.00
% held by Insiders
66.94 %
% held by Institutions
46.85 %
Enterprise Value
1.02 B
Total Shares
58.31 M
Short %
10.69 %
Float Shares
26.88 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F13
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 10%
Micro Cap (rank 815 of 905)
Percentile RankKestra Medical Technologies, Ltd. has significant pipeline risk (13/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KMTS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
KMTS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
KMTS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
KMTS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
KMTS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
KMTS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KMTSKestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference
Kestra Medical Technologies will present at the BofA Securities 2026 Healthcare Conference on May 13, 2026. The presentation is scheduled for 2:20 p.m. Pacific Time. Interested individuals can access the live webcast and replay through the company's investor relations website. Kestra aims to improve patient outcomes in cardiovascular disease with its advanced technologies.
Read more →KMTSKestra Showcases Accelerated Innovation at HRS 2026
Kestra Medical Technologies will exhibit its Cardiac Recovery System at the Heart Rhythm Society's annual meeting in Chicago. The company aims to demonstrate the benefits of its ASSURE WCD platform, which integrates therapy and clinical insights for managing sudden cardiac arrest risk. An updated algorithm, recently approved by the FDA, will also be showcased to enhance patient care.
Read more →KMTSKestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner
Kestra Medical Technologies has been awarded the 2026 USA TODAY Top Workplaces award, recognizing its commitment to employee engagement and a positive work culture. CEO Brian Webster highlighted the importance of collaboration and innovation in developing life-saving technologies. The award is based on confidential feedback from team members, reflecting their trust in the organization.
Read more →KMTSKestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”
Kestra Medical Technologies has been named a finalist for the 'Deal of the Year' at the 2026 GeekWire Awards, recognizing its successful 2025 IPO. This achievement underscores the company's growth and commitment to innovation in the cardiac care sector. Community voting for the awards is open until April 16, 2026, with winners to be announced on May 7, 2026.
Read more →KMTSKestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results
Kestra Medical Technologies reported strong financial results for Q3 FY26, with a 63% increase in revenue to $24.6 million and an expanded gross margin of 52.6%. The company raised its FY26 revenue guidance to $93 million, reflecting robust growth and market share gains. However, it also reported a higher net loss and adjusted EBITDA loss compared to the previous year.
Read more →KMTSKestra Medical Technologies to Report Third Quarter Fiscal 2026 Financial Results on March 17
Kestra Medical Technologies, a prominent player in wearable medical devices, will report its third quarter fiscal 2026 financial results on March 17. A conference call is scheduled for 4:30 p.m. ET, allowing investors to engage with management. The company focuses on improving patient outcomes in cardiovascular disease.
Read more →KMTSKestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery
Kestra Medical Technologies has announced a strategic collaboration with Biobeat Technologies to enhance diagnostic insights for patients using the ASSURE Wearable Cardioverter Defibrillator. The partnership includes a $5 million investment from Kestra into Biobeat's Series B financing. This collaboration aims to integrate Biobeat's innovative blood pressure monitoring technology into Kestra's product offerings, potentially improving patient management during cardiac recovery.
Read more →KMTSKestra Medical Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
Kestra Medical Technologies, a digital healthcare company, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13. The presentation is aimed at showcasing their advancements in wearable medical devices for cardiovascular disease. Interested parties can access the live webcast through their investor relations website.
Read more →KMTSKestra Medical Technologies Reports Second Quarter Fiscal 2026 Financial Results
Kestra Medical Technologies has reported its financial results for the second quarter of fiscal 2026, showcasing a revenue increase of 53% year-over-year to $22.6 million. The company has also expanded its gross margin significantly and increased its revenue guidance for the fiscal year. However, despite this growth, the company continues to experience a net loss and a rise in operating expenses. Kestra is focused on executing its strategy aimed at leadership in the wearable defibrillator market.
Read more →KMTSKestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares
Kestra Medical Technologies, Ltd. announced the pricing of its upsized public offering of 6 million common shares at $23.00 per share, aiming to raise $138 million. The offering is scheduled to close on December 4, 2025, subject to customary conditions. Underwriters have an option for an additional 900,000 shares, underscoring investor confidence. Prominent financial institutions are facilitating the offering, with materials available through SEC filings.
Read more →KMTSKestra Medical Technologies, Ltd. to Report Second Quarter Fiscal 2026 Financial Results
Kestra Medical Technologies, Ltd. will report its second quarter fiscal 2026 financial results on December 11, 2025. A conference call will follow at 4:30 p.m. Eastern Time, with a live and archived webcast available. The company specializes in wearable medical devices and aims to improve patient outcomes in cardiovascular healthcare.
Read more →KMTSKestra Medical Technologies, Ltd. Announces Primary Public Offering of Common Shares
Kestra Medical Technologies, Ltd. has announced a public offering of 5,500,000 common shares to support its operations and growth. The offering is contingent upon market conditions and includes an option for underwriters to purchase additional shares. Proceeds will be allocated to sales, marketing, and research initiatives. The registration statement for the offering has been filed but is not yet effective.
Read more →KMTSKestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results
Kestra Medical Technologies reported preliminary financial results for Q2 FY26, indicating over 50% revenue growth. The company highlighted improvements in gross margin and ongoing commercial success in the wearable defibrillator market. However, the results are preliminary and subject to adjustments, with forward-looking statements carrying inherent risks.
Read more →KMTSLargest Real-World Study of Wearable Defibrillators Confirms Strong Effectiveness and Safety Performance of Kestra’s ASSURE Device
Kestra Medical Technologies announced positive results from the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS), the largest real-world study of wearable defibrillators. The study, presented at the AHA Scientific Sessions 2025, confirmed the device's safety and effectiveness in preventing sudden cardiac death among patients with reduced cardiac function. The findings are expected to inform future clinical practices.
Read more →KMTSKestra Medical Technologies to Present Late-Breaking ACE-PAS Trial Results at AHA 2025, Showcasing Next-Generation Wearable Defibrillator System
Kestra Medical Technologies will present results from the ACE-PAS Trial at the AHA 2025, showcasing their next-generation wearable cardioverter defibrillator system. This study, involving over 20,000 patients, evaluates the device's effectiveness in real-world settings. The late-breaking presentation highlights the significance of wearable defibrillator therapy in cardiac recovery.
Read more →KMTSKestra Medical Technologies to Present at the Stifel 2025 Healthcare Conference
Kestra Medical Technologies, a leader in wearable medical devices, will present at the Stifel 2025 Healthcare Conference on November 11. The presentation aims to showcase their advancements in cardiovascular disease management. Interested individuals can access the live webcast through the company's investor relations website.
Read more →KMTSKestra Appoints Timothy Moran as Chief Business Officer, Strengthening Leadership Team for Next Stage of Growth
Kestra Medical Technologies has appointed Timothy Moran as Chief Business Officer, effective November 3. Moran, with over 25 years of experience in medtech, will oversee business strategy and development. His expertise in cardiac innovation is expected to enhance Kestra's partnerships and accelerate the adoption of its Cardiac Recovery System platform.
Read more →KMTSKestra Showcases Cardiac Recovery System Platform at HFSA 2025, Redefining Sudden Cardiac Arrest Risk Management
Kestra Medical Technologies is showcasing its Cardiac Recovery System platform at the HFSA Annual Scientific Meeting. The platform, featuring the ASSURE Wearable Cardioverter Defibrillator, aims to enhance sudden cardiac death protection and support heart failure recovery. Attendees can experience the platform through demonstrations, highlighting its benefits for clinicians and patients alike.
Read more →KMTSKestra Medical Technologies Appoints Dr. Elizabeth Kwo to Board of Directors
Kestra Medical Technologies has appointed Dr. Elizabeth Kwo as an independent director on its board. Dr. Kwo, a physician and healthcare executive, brings significant experience in digital health and care models. Her role is expected to enhance the company's efforts in advancing its Cardiac Recovery System platform. She has a strong educational background and a history of founding healthcare companies.
Read more →KMTSKestra Medical Technologies Reports First Quarter Fiscal 2026 Financial Results
Kestra Medical Technologies reported a strong start to fiscal 2026, with over 50% revenue growth in the first quarter. The company has increased its revenue guidance for FY26 to $88 million, reflecting a 47% growth compared to the previous fiscal year. Key operational advancements include enhancements in revenue cycle management and market share capture in the wearable defibrillator market.
Read more →KMTSKestra Medical Technologies, Ltd. to Report First Quarter Fiscal 2026 Financial Results
Kestra Medical Technologies, Ltd. will report its financial results for the first quarter of fiscal 2026 on September 11. A conference call to discuss these results will be held at 4:30 p.m. Eastern Time. The company specializes in wearable medical devices aimed at improving patient outcomes in cardiovascular health through innovative technologies.
Read more →KMTSKestra Medical Technologies Wins 2025 Top Workplaces Industry Award, A National Recognition
Kestra Medical Technologies has been awarded the 2025 Top Workplaces Industry award by Energage, recognizing its commitment to a people-first workplace culture. This accolade highlights the dedication of its employees towards improving patient outcomes in the healthcare sector. The award is based on feedback from an employee engagement survey, affirming Kestra's strong workplace culture.
Read more →KMTSKestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Kestra Medical Technologies reported strong financial results for Q4 and FY25, reflecting significant revenue growth and improved gross margins. In Q4, revenue reached $17.2 million, a 71% increase year-on-year, while overall FY25 revenue was reported at $59.8 million, a 115% rise from FY24. Despite these gains, the company also noted a higher net loss of $51.1 million for Q4, impacted by increased operating expenses related to share-based compensation and its recent IPO. Looking ahead, Kestra has projected a revenue guidance of $85 million for FY26, representing a further increase of 42% compared to FY25.
Read more →KMTSKestra Medical Technologies, Ltd. to Report Fourth Quarter and Fiscal Year 2025 Results on July 15
Kestra Medical Technologies, Ltd. has announced that it will report its fourth quarter and fiscal year 2025 financial results on July 15. The company specializes in wearable medical devices and digital healthcare solutions aimed at improving patient outcomes in cardiovascular disease. Following the results, a conference call will be held at 4:30 p.m. Eastern Time, with a live and archived webcast available for participants. Investors are encouraged to register for the call in advance through the company's investor relations website.
Read more →KMTSKestra Medical Technologies Announces Inclusion in the Russell 2000 and Russell 3000 Indexes
Kestra Medical Technologies has announced its inclusion in the Russell 3000 Index, which will be effective after the U.S. market closes on June 27, 2025. This automatic inclusion in the Russell 2000 Index represents a critical milestone for the company following its recent initial public offering in March 2025. Kestra focuses on transforming outcomes in cardiovascular care through innovative wearable medical devices and digital health technologies. The recognition may enhance its visibility and credibility in the market.
Read more →KMTSKestra Medical Technologies Announces Appointment of Conor Hanley to its Board of Directors
Kestra Medical Technologies has appointed Conor Hanley as an independent director to its board, effective June 4, 2025. Hanley, who has extensive experience in medical technology and cardiac care, aims to provide strategic guidance as the company expands its ASSURE® system. His background includes leadership roles at ResMed and founding BiancaMed, reflecting a strong commitment to innovation in cardiovascular healthcare.
Read more →KMTSKestra Medical Technologies to Participate in Upcoming Investor Conferences
Kestra Medical Technologies, Ltd. is set to participate in two upcoming investor conferences: the BofA Securities 2025 Health Care Conference on May 14 and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11. The company specializes in wearable medical devices and digital healthcare, aiming to improve patient outcomes in cardiovascular care with its advanced monitoring technologies. Interested individuals can access the presentations through the company's investor relations website.
Read more →KMTSKestra Showcases Real-World Outcomes for ASSURE WCD at Heart Rhythm 2025
Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) presented new real-world data on its ASSURE Wearable Cardioverter Defibrillator at the Heart Rhythm 2025 conference. The findings showed significant patient compliance and effective management of ventricular arrhythmias in a community setting. This research underscores the advantages of using an advanced practice provider-driven care model for delivering cardiac therapy. Kestra aims to improve patient outcomes through connected cardiac recovery solutions.
Read more →KMTSKestra Medical Technologies to Showcase Innovation in Sudden Cardiac Arrest Protection and Recovery at Heart Rhythm 2025
Kestra Medical Technologies will showcase its ASSURE® system at Heart Rhythm 2025, aiming to enhance protection and recovery for patients at risk of sudden cardiac arrest. This event marks the company's first major showcase following its IPO, and it will feature new clinical data related to the ASSURE system's impact. Additionally, Kestra will emphasize its commitment to innovation and equity in cardiovascular care by sponsoring the Women in EP Luncheon for the fourth consecutive year.
Read more →KMTSKestra Medical Technologies Reports Third Quarter Fiscal 2025 Financial Results
Kestra Medical Technologies reported its financial results for Q3 FY25, showcasing an impressive revenue increase of 82% year-over-year, attributed to a rise in prescriptions and better revenue management. The gross margin saw a significant improvement, climbing to 43.4%. Despite strong revenue growth, operating expenses also rose, leading to a slight increase in net loss. The company continues to expand its market presence following its recent IPO, with contracts now covering over 285 million lives in the U.S.
Read more →KMTSKestra Medical Technologies, Ltd. to Report Third Quarter Fiscal 2025 Financial Results on April 14
Kestra Medical Technologies, Ltd. has announced that it will report its financial results for the third quarter of fiscal 2025 on April 14. The company, which specializes in wearable medical devices and digital healthcare solutions, will host a conference call to discuss these results. Participants are encouraged to register on the investor relations website, emphasizing the company's focus on transparency and communication with stakeholders.
Read more →KMTSKestra Medical Technologies, Ltd. Announces Full Exercise and Closing of Underwriters' Over-Allotment Option in Initial Public Offering
Kestra Medical Technologies, Ltd. has announced the full exercise and closing of underwriters' over-allotment option during its initial public offering. A total of 1,782,352 shares of common stock were purchased at $17.00 per share, bringing the total number of shares sold in the IPO to 13,664,704. The offering yielded approximately $232 million in gross proceeds before expenses. Leading underwriters included BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler.
Read more →KMTSKestra Medical Technologies, Ltd. Announces Closing of Upsized Initial Public Offering
Kestra Medical Technologies, Ltd. has announced the successful closing of its upsized initial public offering, offering 11,882,352 common shares at a price of $17.00 per share. This move generated approximately $202 million in gross proceeds. The company's shares began trading on the Nasdaq Global Select Market under the ticker symbol 'KMTS' on March 6, 2025. The offering was underpinned by several reputable financial institutions acting as bookrunners.
Read more →KMTSKestra Medical Technologies, Ltd. Announces Pricing of Upsized Initial Public Offering
Kestra Medical Technologies, Ltd. has announced the pricing of its upsized initial public offering, offering 11,882,352 common shares at $17.00 per share. The offering is expected to generate around $202 million in gross proceeds, excluding potential additional shares due to underwriter options. The shares are set to begin trading on the Nasdaq Global Select Market under the ticker symbol 'KMTS'. The closing of the offering is anticipated to occur on March 7, 2025, following the fulfillment of customary conditions.
Read more →KMTSKestra Medical Technologies, Ltd. Announces Launch of Initial Public Offering
Kestra Medical Technologies, Ltd. has announced the launch of its initial public offering of 10,000,000 common shares, with a potential for an additional 1,500,000 shares through an over-allotment option. The price for the shares is anticipated to be between $14.00 and $16.00. Kestra has applied to list its shares on the Nasdaq under the ticker symbol 'KMTS'. Major financial institutions are acting as lead bookrunners for this offering, which aims to expand the company's reach in the wearable medical device and digital healthcare market.
Read more →KMTSKestra Medical Technologies, Ltd. Appoints Neil Bhalodkar as Vice President of Investor Relations
Kestra Medical Technologies, Ltd. has appointed Neil Bhalodkar as the new Vice President of Investor Relations, effective March 3, 2025. Bhalodkar brings over two decades of experience in investor relations and corporate finance, having previously led the investor relations function at Inari Medical and helped launch Axonics. The company's leadership is confident that his expertise will aid in expanding the wearable defibrillator market and strengthening communications with investors.
Read more →KMTSKestra Medical Technologies, Ltd. Appoints Al Ford as Chief Commercial Officer
Kestra Medical Technologies announced the appointment of Al Ford as Chief Commercial Officer (CCO). Ford, who brings 20 years of experience in MedTech, will lead the company's sales strategies and operations. His expertise, particularly in defibrillation technologies, is anticipated to enhance the commercial team. Kestra aims to improve patient outcomes in cardiovascular disease through its innovative device portfolio.
Read more →Competitive Position
How KMTS ranks across every disease it competes inCompetitive Position is a premium feature
See how KMTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial